Hikma Pharmaceuticals


Time to capitalise on Hikma’s ongoing (share price) momentum

17/05/24 -"We have incorporated higher royalty payments in 2024 related to the sale of the generic version of sodium oxybate (medicine to treat symptoms of narcolepsy, i.e. sudden muscle weakness and excessive ..."

Pages
47
Language
English
Published on
17/05/24
You may also be interested by these reports :
14/06/24
When we last teased Lundbeck’s (BUY; Denmark) story in May 2023, the share price had fiercely recovered (>45%) from the October 2022 lows, and the ...

12/06/24
Portfolio news flow likely to support NAV growth in the medium term

12/06/24
Siegfried to acquire early-phase CDMO in the U.S., outlook reiterated

04/06/24
GSK lost c.9% (i.e. £6.2bn or $7.9bn) of its market cap yesterday after the Delaware (US) Court, in Zantac litigations, allowed the plaintiffs’ ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO